glp-1 cancer prevention weight-loss drugs are transforming lives — but what do they really mean for people facing cancer? We brought together perspectives from researchers, clinicians and patients navigating the promise and the tradeoffs GLP-1s in Oncology: Nursing Insights

Description

The 4mg arm coming in at 21% is equally impressive

O'Neil et al., 2018)

Orforgliprons ATTAIN program showed roughly 11-12% mean weight loss at 72 weeks at the highest dose

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

Monitoring protocols : Establish a clear monitoring schedule including regular weight checks, vital signs (blood pressure and heart rate after each stimulant dose change and at least every 6 months), assessment of ADHD symptoms, evaluation of eating patterns and nutritional adequacy, and screening for adverse effects from either medication